• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Data backs splanchnic ablation procedure from Axon Therapies

Data backs splanchnic ablation procedure from Axon Therapies

March 22, 2023 By Sean Whooley

Axon Therapies Satera Ablation Catheter s
The Satera ablation cathether. [Image courtesy of Axon Therapies]
Axon Therapies today announced positive six-month results from a trial for its proprietary splanchnic ablation for volume management (SAVM) therapy.

Dr. Marat Fudim, advanced heart failure specialist at Duke University Medical Center, presented results at the Technology and Heart Failure Therapeutics (THT) Conference in Boston. The data came from a roll-in cohort for the REBALANCE-HF investigational device exemption feasibility trial.

Santa Clara, California-based Axon Therapies said its data remains consistent with prior results for the SAVM therapy. The novel, frontline therapy uses an outpatient ablation procedure. It aims to rebalance volume distribution for heart failure patients with preserved ejection fraction (HFpEF).

In addition to the positive results, Axon Therapies said it expects its trial to reach full enrollment by the end of the month. The approximately 120-patient study should provide full results in 2024.

“The SAVM procedure offers an exciting option to treat an underlying cause of heart failure in a patient population that currently has limited treatment options available,” said Fudim. “Although early data, it is promising to see positive patient benefits sustained for six months and we look forward to further demonstrating how SAVM has the potential to benefit the HFpEF patient population.”

About the Axon Therapies REBALANCE HF trial

The trial evaluates the safety and efficacy of SAVM with the Axon Satera ablation catheter. This ablation system enables targeted ablation of the overactive sympathetic nervous system.

As an implant-free, catheter-based procedure, it aims to restore volume balance and stop disease progression while improving heart failure symptoms.

Primary endpoints for the trial include clinical improvements in pulmonary capillary wedge pressure (PCWP) with exercise and patient quality of life metrics.

The roll-in cohort includes 26 patients who successfully underwent SAVM with a strong safety profile. They showed a sustained improvement in PCWP with exercise. The subjects also demonstrated improvements in functional capacity, symptoms, and overall health status. All these improvements appeared at one month and extended to six.

Axon Therapies expects findings to inform its pivotal trial, slated to begin in late 2023.

Dr. Shanjiv Shah, national principal investigator for the trial, explained that the diversity of HFpEF may impact clinical outcomes. For that reason, the investigators opted for a larger feasibility trial. They aim to identify potential responder groups at an earlier stage, he noted.

“As we continue to collect follow-up data for the REBALANCE-HF feasibility trial, this information will help guide the final pivotal trial design,” Shah said.

Shah serves as an advanced heart failure specialist and director of research for the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine in Chicago.

Filed Under: Cardiovascular, Catheters, Clinical Trials, News Well Tagged With: Axon Therapies, THT 2023

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy